Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-07-02-Speech-1-106-000"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-07-02"^^xsd:date2
dcterms:Is Part Of	lp_eu:Customs enforcement of intellectual property rights (debate)2
dcterms:Language	"sv"^^xsd:language2
lpv:document identification number	"en.20120702.19.1-106-000"2
lpv:hasSubsequent	lp_eu:2012-07-02-Speech-1-107-0002
lpv:speaker	lp:Anna Hedh2
lpv:spokenAs	unknown; Arbetarepartiet- Socialdemokraterna (2009-07-14--2014-06-30)3 member; S&D (2009-07-14--2014-06-30)3 substitute; IMCO (2012-01-19--2014-06-30)3 substitute; Delegation for relations with the countries of Central America (2009-09-16--2014-06-30)3 member; LIBE (2012-01-19--2014-06-30)3 vice-chair; Delegation for relations with Switzerland and Norway and to the EU-Iceland Joint Parliamentary Committee and the European Economic Area (EEA) Joint Parliamentary Committee (2011-03-29--2014-06-30)3 substitute; CRIM (2012-03-28--2013-10-23)3
lpv:translated text	"Mr President, I welcome the review of the regulation, and I would like to thank Mr Creutzmann for his excellent cooperation with the shadow rapporteurs. Many of the goods that are covered by this regulation are directly intended for consumers, for example, food, medicines and toys. In certain cases, they can present a direct danger to life and health. Therefore, the starting point for the Group of the Progressive Alliance of Socialists and Democrats in the European Parliament was to ensure a safe internal market for the sake of our consumers. For example, we ensured that goods imported for private use and parallel imports are exempt from the scope of the regulation. In the Committee on the Internal Market and Consumer Protection, we supported passages concerning the inclusion in the regulation of goods in transit. Unfortunately, information was received after the vote that made us aware of the fact that this decision could prevent access to legal generic drugs in developing countries. Therefore, my S&D Group colleagues in the Committee on the Internal Market and Consumer Protection, the Committee on Legal Affairs and the Committee on International Trade and I have taken a decision to table a number of amendments in order to ensure that this decision does not prevent access to generic drugs in developing countries. The key amendment concerns the fact that goods in transit should be excluded from the scope, except when there is clear and convincing evidence that they are intended for the EU market. As a consequence of our position with regard to generics, we will also vote against Mr Creutzmann’s proposal for a simplified procedure for all types of goods that represent infringements, as this simplified procedure should not be applied to goods other than counterfeit and pirated goods, otherwise we once again risk causing problems for generic drugs in transit. At present, neither the Commission’s proposal nor the report by the Committee on the Internal Market and Consumer Protection pay sufficient attention to the risk of legal generic drugs being confiscated and/or destroyed at the border. The proposal therefore poses the serious risk that patients in developing countries will not have continued access to good quality, legitimate generic drugs. The S&D Group cannot be involved in impeding access to generic drugs, which, for many patients, constitute a lifeline."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph